抗MPO-ANCAs和抗PR3-ANCAs联合血清肿瘤标志物对乳腺癌的诊断作用

Role of Anti-MPO-ANCAs and Anti-PR3-ANCAs Combined with Serum Tumor Markers in the Diagnosis of Breast Cancer

摘要: 目的：本研究旨在检测乳腺癌患者抗中性粒细胞胞浆自身抗体(ANCA)、癌胚抗原(CEA)、糖类抗原125 (CA125)和糖类抗原153 (CA153)等血清肿瘤标志物，分析抗蛋白酶3 (PR3)-ANCAs、抗髓过氧化物酶(MPO)-ANCAs与以上血清肿瘤标志物联合检测乳腺癌的临床价值，并分析其与乳腺癌的相关性。方法：抽取2024年1月~2024年9月于眉山市中医医院就诊的90例乳腺癌患者作为观察组，另选取90例健康体检者作为对照组，测定各血清样本抗MPO-ANCAs、抗PR3-ANCAs、CEA、CA125和CA153水平，评估以上指标单独及联合检测对乳腺癌的诊断价值。结果：观察组抗MPO-ANCAs、抗PR3-ANCAs、CEA、CA125和CA153水平显著高于对照组(P < 0.05)；Her-2过表达型抗MPO-ANCAs、抗PR3-ANCAs、CEA、CA125和CA153水平高于Luminal A型、Luminal B型和三阴型(P < 0.05)；抗MPO-ANCAs、抗PR3-ANCAs、CEA、CA125和CA153水平联合诊断乳腺癌敏感度及特异度显著高于单一指标诊断，AUC高于单一指标诊断(P < 0.05)。结论：抗MPO-ANCAs、抗PR3-ANCAs、血清肿瘤标记物(CEA、CA125、CA153)检测对乳腺癌诊断具有一定价值，其联合检测可提高乳腺癌诊断的敏感度与特异性，提高其诊断效能。乳腺癌Her-2过表达型患者抗MPO-ANCAs、抗PR3-ANCAs、CEA、CA125和CA153水平高于其他亚型患者，以上指标可能与疾病发展及病情恶化相关，联合检测有助于了解病情发展情况。

Abstract: Objective: This study aimed to detect serum tumor markers such as anti-neutrophil cytoplasmic autoantibodies (ANCA), carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125) and carbohydrate antigen 153 (CA153) in breast cancer patients, analyze the clinical value of combined detection of anti-proteinase 3 (PR3)-ANCAs, anti-myeloperoxidase (MPO)-ANCAs and the above serum tumor markers for breast cancer, and explore their correlation with breast cancer. Methods: Methods: 90 patients with breast cancer who visited Meishan Hospital of Traditional Chinese Medicine from January 2024 to September 2024 were selected as the observation group, and 90 healthy people were selected as the control group. The levels of anti MPO ANCAs, anti PR3 ANCAs, CEA, CA125 and CA153 in serum samples were measured, and the diagnostic value of the above indicators in breast cancer was evaluated individually and jointly. Results: The levels of anti-MPO-ANCAs, anti-PR3-ANCAs, CEA, CA125 and CA153 in the observation group were significantly higher than those in the control group (P < 0.05). The levels of anti-MPO-ANCAs, anti-PR3-ANCAs, CEA, CA125 and CA153 in Her-2 overexpression group were higher than those in Luminal A, Luminal B and triple-negative groups (P < 0.05). The sensitivity and specificity of combined detection of anti-MPO-ANCAs, anti-PR3-ANCAs, CEA, CA125 and CA153 for breast cancer were significantly higher than those of single indicator detection, and the area under the curve (AUC) was also higher than that of single indicator detection (P < 0.05). Conclusion: Combined detection of anti-MPO-ANCAs and anti-PR3-ANCAs with serum tumor markers (CEA, CA125, CA153) can improve the diagnostic efficacy of breast cancer. The levels of anti-MPO-ANCAs, anti-PR3-ANCAs, CEA, CA125 and CA153 are highly expressed in breast cancer patients, especially in those with the Her-2 overexpression subtype. The above indicators may be related to the development and deterioration of the disease, and the combined detection is helpful to understand the development of the disease.